Letrozole Combination Increases PFS In ER+ and HER2-Negative Breast Cancer
Afinitor Significantly Reduced Tumor Size In TSC-Related Renal Angiomyolipomas
Nexavar Improves PFS In Phase III Trial
Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease
Ibrutinib Produces 68% Overall Response Rate in Phase II Trial
Researchers Uncover Tumors Sensitive to Chemotherapy
Researchers Find Genetic Alterations in Triple-Negative Cancers Following Treatment
Existing HER2 Drugs May Help More In Breast Cancer Treatment
Smoking Intensity and Markers Predict Cancer Aggressiveness
Low Adiponcetin Hormone Levels Linked to Increased Cancer Risk
No Difference in Toxicity Between IMRT and PRT In Medicare Patients
NCI CTEP Approved Trials For the Month of January
FDA Expands Gleevec Indication For Children with Ph+ ALL
Trending Stories
- “Backwater to Blockbuster” chronicles the previously untold story of the explosive growth of St. Jude Children’s Research Hospital
In a conversation with Deborah Doroshow, co-authors Chuck Sherr and Bill Evans discuss their collaborative writing process - Prasad’s “deceit,” plus, ODAC’s tough decision against biomarker-based progression assessment (for now)
- FDA’s second rejection of Replimune’s melanoma treatment stirs worry among oncologists, patients
“Patients are owed another review.” - Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- Vinay Prasad’s CV inaccurately claims past membership on the President’s Cancer Panel
- DOJ alleges that Yale and UCLA discriminated based on race in medical school admissions
